Bio X Cell today announced the launch of the first commercially available ready-to-use anti-mouse PD-L1 × TIGIT × LAG3 trispecific antibody, introducing a new approach to studying combinatorial checkpoint biology in vivo. The tetravalent trispecific format enables simultaneous interrogation of three complementary immune checkpoint pathways within a single experimental system, expanding the experimental approaches available for investigating coordinated checkpoint biology in standard mouse models.
As LAG3 gains increasing clinical validation and TIGIT combinations continue to be explored across oncology programs, the need for preclinical tools that reflect the combinatorial nature of checkpoint biology has grown. The PD-L1 × TIGIT × LAG3 trispecific enables investigators to study T-cell exhaustion, immune suppression, and combinatorial checkpoint blockade within a single in vivo system, reducing the variability and experimental complexity associated with multi-agent study designs.
"Checkpoint biology is inherently combinatorial, and researchers increasingly need tools that reflect that complexity," said Kaitlyn Bushey, Director of Development and Strategic Alliances at Bio X Cell. "This trispecific format brings PD-L1, TIGIT, and LAG3 together within a single in vivo system, expanding the experimental approaches available for studying checkpoint interactions."
The antibody was recombinantly engineered with a murine IgG2a constant region for compatibility in standard mouse models and manufactured to Bio X Cell's in vivo-ready quality standards, including ultra-pure, carrier-free formulations and low endotoxin levels designed to minimize reagent-driven variability and support reproducible in vivo studies.
The launch marks the latest example of Bio X Cell’s approach to defining in vivo-ready antibody standards as research demands evolve. By expanding beyond traditional monoclonal antibodies into advanced recombinant formats and custom engineering capabilities, Bio X Cell is helping researchers investigate increasingly complex biological questions across modern preclinical workflows.
Together, these catalog and custom capabilities provide a unified path from early mechanistic discovery through advanced multispecific development, helping research teams maintain continuity in quality, production, and experimental design across the preclinical workflow.
For information on Bio X Cell’s multispecific antibody portfolio and custom engineering capabilities, visit https://bioxcell.com/
